Drug intelligence / Profile preview

Compound 7f

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

Compound 7f is a small molecule and a resynthesized derivative of belinostat, an established histone deacetylase (HDAC) inhibitor. It has demonstrated potent antiproliferative activity against MOPC-315 myeloma cells, showing a 3.5-fold higher potency than belinostat. Furthermore, Compound 7f exhibits more potent inhibitory activity against histone deacetylase 6 (HDAC6) compared to belinostat. Preclinical studies have also shown a strong synergistic interaction when combined with the proteasome inhibitor bortezomib, suggesting its potential as a therapeutic agent for multiple myeloma.

Targets

HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on Compound 7f.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 7f.

Explore the full profile